Nuwiq - Human Coagulation Factor VIII (rDNA) (Simoctocog Alfa)

Indication

Nuwiq® is indicated for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) of all age groups.

Presentation

Supplied as powder and solvent for solution for injection, with all vial strengths in a 2.5 mL infusion volume and supplied with a pre-filled syringe. Available in vials of: 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU.

Convenient twice-weekly dosing to effectively prevent bleeds in patients on personalised prophylaxis1:

• 83% of patients free from spontaneous bleeds;
• 57% of patients treated twice-weekly or less;
• 0 inhibitors or severe treatment related adverse events.

In 66 adult patients with haemophilia A on personalised prophylaxis with Nuwiq®1 Favourable rate of inhibitors in previously untreated patients (PUPs) demonstrated in NuProtect, the largest prospective study in true PUPs with a single FVIII product2:

• 17.6% cumulative incidence of high-titre inhibitors;
• 27.9% cumulative incidence of all inhibitors;
• No inhibitors in patients with non-null F8 mutations.

In 105 PUPs in the NuProtect Study2. Zero inhibitors in over 190 previously treated patients switching to Nuwiq®  in clinical trials3